ELI LILLY & Co business relationships

“We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe.” SEC filing

“(2) In collaboration with Almirall, S.A. in Europe.” SEC filing

“In 2025, 2024, and 2023, three wholesale distributors in the U.S.-McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.-each accounted for a significant percentage of our consolidated revenue.” SEC filing

“In 2025, 2024, and 2023, three wholesale distributors in the U.S.-McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.-each accounted for a significant percentage of our consolidated revenue.” SEC filing

“In 2025, 2024, and 2023, three wholesale distributors in the U.S.-McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.-each accounted for a significant percentage of our consolidated revenue.” SEC filing

“...iopharmaceutical Co., Ltd., Aro Biotherapeutics, Arrowhead and its collaborators, AstraZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, SanegeneBio, Sarepta Therapeutics, Inc., Silence Therapeutics plc, Takeda Pharmaceutical Company Ltd., and W...” SEC filing

“In December 2023, Organon announced an agreement with Lilly to become the sole distributor and promoter of the migraine medicine Emgality in Europe.” SEC filing

“...s range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes I...” SEC filing

“Between 2020 and 2025, we negotiated an increased mean royalty rate of 4.2% across our programs with downstream participation signed in the period and our agreement to partner our COVID-19 antibody asset to Eli Lilly and Company.” SEC filing

“The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement.” SEC filing

“If Lilly does not opt-in to co-develop and co-commercialize a licensed product, Lilly is obligated to pay the Company a percentage of any royalties received from Verve for sales of such product, subject to certain caps on a licensed product-by-licensed product basis.” SEC filing

“We also have several discovery-stage programs targeting this novel biology, which we will continue to advance through our ongoing collaborations with Lilly and Novartis.” SEC filing

“In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics.” SEC filing

“In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics.” SEC filing

“We have licensed to Novartis rights to ruxolitinib outside of the United States and worldwide rights to our MET inhibitor compounds, including TABRECTA, and licensed to Lilly worldwide rights to baricitinib.” SEC filing

“These include OLUMIANT (baricitinib), which is licensed to our collaborative partner Eli Lilly and Company ("Lilly"), and JAKAVI (ruxolitinib) and TABRECTA (capmatinib), which are licensed to Novartis.” SEC filing

“Royalty revenues on commercial sales for OLUMIANT by Lilly are estimated based on information provided by Lilly.” SEC filing

“Additionally, we maintain a license agreement with Eli Lilly and Company ("Eli Lilly"), under which we receive royalty payments for certain licensed intellectual property.” SEC filing

“...of gross profit share and royalty payments for NGENLA ® and Pfizer's Genotropin, a $ 7.0 million upfront payment from Regeneron, $ 4.3 million in royalty revenue from Eli Lilly following the commercial launch of Mazdutide in China and $ 7.4 million from contract manufacturers' commercial milestones.” SEC filing

“Our full-price retail store strategy for the Lilly Pulitzer brand includes operating full-price retail stores in higher-end lifestyle shopping centers and malls, resort destinations and brand-appropriate street locations.” SEC filing

“Lilly Pulitzer's net sales to its 10 largest wholesale customers represented approximately 10% of Lilly Pulitzer's net sales in Fiscal 2025 with its largest customer representing less than 5% of Lilly Pulitzer's net sales.” SEC filing

“Lilly Pulitzer's net sales to its 10 largest wholesale customers represented approximately 10% of Lilly Pulitzer's net sales in Fiscal 2025 with its largest customer representing less than 5% of Lilly Pulitzer's net sales.” SEC filing

“...primarily due to a decrease of $18.8 million, or 37%, in the legacy Quanterix business due to the macro-economic conditions impacting demand for large projects from pharmaceutical customers and the completion of an agreement with Eli Lilly and Company which generated $4.5 million of revenue in 2024.” SEC filing

“In February 2022, the Company and Eli Lilly and Company ("Lilly") entered into a Technology License Agreement (the "Lilly License") under which Lilly granted a non-exclusive license to Lilly's proprietary p-Tau 217 antibody technology for use by the Company in RUO products, services, and future in v...” SEC filing

“In February 2025, we expanded our research collaboration with Lilly to add an undisclosed target to the collaboration.” SEC filing

“In April 2022, we entered into a licensing agreement with Lilly that granted us exclusive worldwide rights to develop and” SEC filing

“We have also established a collaboration and clinical supply agreement with Eli Lilly to evaluate zugo-cel together with pirtobrutinib in aggressive B-cell lymphomas, further expanding the program's development in oncology.” SEC filing

“Based on the strength of our molecular CKD patient database, we have built four partnerships in kidney diseases in the last almost ten years with prominent pharmaceutical companies such as Bayer, Vifor (now "CSL Vifor"), Novo Nordisk, Eli Lilly, and Chinook (now a Novartis company).” SEC filing

“Although we previously entered into a license agreement with Eli Lilly and Company (Lilly) in 2017 (the Lilly Agreement) to develop and commercialize rezpegaldesleukin, on April 23, 2023, we received from Lilly a notice of at-will termination of the Lilly Agreement, and on April 27, 2023, we announc...” SEC filing

“Following the termination of our collaboration agreement with Eli Lilly and Company, we do not have a collaboration agreement for rezpegaldesleukin.” SEC filing

“In the event Lilly fails to promptly and completely transfer to us any additional needed materials or we are not able to independently source these documents, records and data (e.g., from vendors or third parties who may also have these materials), the continued clinical development of rezpegaldesle...” SEC filing

“Under the Lilly Agreement, we had the right to opt-out of co-funding the ocadusertib development activities in the US, Europe and Japan at two different specified times and as a result receive lesser royalties from sales.” SEC filing

“Global Exclusive License Agreement with Lilly” SEC filing

“We also have a RIPK1 inhibitor program in clinical development that is being led by our partner Lilly.” SEC filing

“Morphomer Tau small molecule - 2018 license agreement with Eli Lilly and Company” SEC filing

“Lastly, our collaboration agreements with Lilly, Janssen, Lantheus and Takeda (in the case of Takeda, if it exercises its option under our agreement) provide each partner with control over, and responsibility for, the clinical development process, including obtaining regulatory and marketing approva...” SEC filing

“For instance, we entered into clinical trial collaboration and supply agreements with Eli Lilly, pursuant to which our collaboration counterparties will supply doses of ramucirumab for use in certain clinical trials.” SEC filing

“The Company accounted for the arrangement under ASC 606 as the Company concluded it has a customer relationship with Lilly.” SEC filing

“• Advance our lead precision oncology product candidate, FHD-909, through clinical development in patients with NSCLC and with select solid tumors with partner Lilly.” SEC filing

“We are aware of amylin small molecules in preclinical development by: Eli Lilly, Eccogene, Nxera, Iktos/Cube Biotech strategic collaboration, Alveus Therapeutics and Ambrosia Biosciences.” SEC filing

“In August 2025, we announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982), which intends to support the evaluation of atebimetinib in combination with olomorasib in a planned clinical trial of patients with locally advan...” SEC filing

“generic version of Axiron in the United States, through a marketing and distribution agreement between Lilly and Company and a leading” SEC filing

“...aGTx Limited and Meira UK II (collectively, "Meira"), entered into a strategic collaboration and license agreement with Eli Lilly and Company ("Lilly") (the "Lilly Collaboration Agreement") for the research, development and commercialization of genetic medicines in and related to the area of ophthal...” SEC filing

“| | ● | | We entered into a strategic collaboration with Lilly, granting Lilly worldwide exclusive rights to the AAV-AIPL1 program for Leber congenial amaurosis 4 (LCA4) and access to additional ocular and gene regulation assets.” SEC filing

“In addition, Transcenta Holding has licensed the Chinese rights to the anti-sclerostin antibody blosozumab from Eli Lilly and Company ("Lilly") and plans to develop it for osteoporosis.” SEC filing

“...for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Eli Lilly, Merck, Novartis Pharmaceuticals Corporation ("Novartis"), Pfizer, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” SEC filing

“To date the Lilly collaboration has been the main source of revenue to the Company.” SEC filing

“ASC 808 does not provide guidance on how to account for the activities under the collaboration, and the Company determined that Lilly did not meet the definition of a customer under ASC 606, Revenue from Contracts with Customers.” SEC filing

“On January 31, 2022, the Company entered into a Clinical Trial Collaboration and Supply Agreement (the "Lilly Agreement") with Eli Lilly and Company ("Lilly").” SEC filing

“As a result of this approval, the Company met a milestone under its license agreement with Eli Lilly and Company (Lilly) that required the Company to make a license payment of $ 10.0 million to Lilly, which was accrued in the Company's Consolidated Balance Sheets as of December 31, 2025 and represen...” SEC filing

“...July 2024, we entered into a royalty purchase agreement with OMERS pursuant to which we sold to OMERS a portion of our future royalty payments and the remaining anniversary milestones associated with the license to Lilly (see "-Royalty Purchase Agreement with OCM IP Healthcare Portfolio LP" above).” SEC filing

“Under the license agreement, Lilly has paid us upfront, anniversary, regulatory and commercial milestone payments.” SEC filing

“License Agreement, between Eli Lilly and Company and Dekkun Corporation, effective as of January 3, 2011 (incorporated by reference to Exhibit 10.4 to the Company's registration statement on Form S-4, as filed on September 26, 2016).” SEC filing

“We have a clinical collaboration agreement with Eli Lilly and Company, or Lilly, that will supply Verzenio ® (abemaciclib), a CDK4/6 inhibitor, for use in combination with TNG456 in our ongoing Phase 1/2 clinical trial focused on MTAP-deleted GBM.” SEC filing

“We have entered into separate clinical collaboration and supply agreements with RevMed, Lilly, and Erasca, under which we plan to conduct combination clinical trials with RevMed's RAS(ON) multi- and G12D-selective inhibitors, Lilly's abemaciclib and Erasca's pan-RAS molecular glue, respectively.” SEC filing

“Redwire has launched 42 PIL-BOXes through December 31, 2025, for our partners including, but not limited to, Bristol Myers Squibb and Eli Lilly.” SEC filing

“For example, in May 2024, we entered into a research, collaboration and license agreement with Eli Lilly to discover and generate novel tumor-targeting radiopharmaceuticals.” SEC filing

“We also have a discovery collaboration with Eli Lilly and Company, or Eli Lilly, to generate novel anticancer radiopharmaceuticals against targets beyond the scope of our unpartnered pipeline programs.” SEC filing

“• The Lilly License Agreement; and” SEC filing

“In 2025, our discontinued operations generated $2.0 million of revenue through SEED's research collaboration and license agreement with Eli Lilly and our continuing operations did not generate any revenue.” SEC filing

“SEED ' s research collaborations with Eli Lilly and Eisai” SEC filing

“The Lilly Collaboration Agreement is within the scope of ASC 808, as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement.” SEC filing

“...standing of Aβ biology described above, PMN310 was designed to be more selective for the toxic oligomer of amyloid than other anti-Aβ antibodies such as aducanumab from Biogen, lecanemab, co-developed by Eisai Co. and Biogen, donanemab from Lilly, ACU193 from Acumen and the Prothena PRX012 antibody.” SEC filing

“...tune 100 pharmaceutical and healthcare companies such as Pfizer, Merck, AbbVie, Bausch & Lomb, ThermoFisher Scientific, Eli Lilly and Company, FUJIFILM Diosynth Biotechnologies USA, and Fresenius Kabi, as well as government agencies including the National Institutes of Health ("NIH"), the U.S. Depar...” SEC filing

“...Athanor Agreement, we agreed to pay an amount equal to 2% of Net Sales (as defined in the Athanor Agreement) for the Product (as defined in the Athanor Agreement) to the extent such Net Sales (collectively, the "Net Sales Payments") are the subject of a royalty payment under the 2023 Lilly License.” SEC filing

“Our ability to continue to develop and commercialize tibulizumab is dependent on the use of certain intellectual property that is licensed to us from Lilly.” SEC filing

“(marketed by Lilly ICOS LLC, a joint venture between Eli Lilly and Company and ICOS Corporation) and their generic forms.” SEC filing

“...ose being conducted by Anocca, Arvinas, Astellas Pharma Inc., AstraZeneca, Beijing DCTY Biotech Co. Ltd., D3 BIO, Inc., Eli Lilly, Elicio Therapeutics, GenFleet Therapeutics (licensed to Verastem Oncology), Hyperway Pharmaceutical Co. Ltd., Incyte Corporation, Jiangsu Hansoh Pharmaceutical Group Co....” SEC filing

“Pursuant to the terms of the Lilly License Agreement, Lilly granted the Company an exclusive, worldwide, royalty bearing, sublicensable license under certain technology, patent rights, know-how and proprietary materials related to certain compounds, to research, develop, and commercialize such compo...” SEC filing

“The revenue we generate from Elunate is primarily comprised of revenue from the sales of Elunate to Eli Lilly which we manufacture and sell at cost, promotion and marketing services to Eli Lilly and royalty revenue.” SEC filing

“Additionally, Eli Lilly is obligated to pay us tiered royalties from 15% to 20% annually on sales made of fruquintinib in China and Hong Kong, the rate to be determined based upon the dollar amount of sales made for all products in that year.” SEC filing

“Fruquintinib is partnered with Eli Lilly under the brand of Elunate in China.” SEC filing

“For Fruzaqla, Elunate and Orpathys, they represent total sales to third parties as provided by Takeda, Eli Lilly and AstraZeneca, respectively.” SEC filing

“License Agreement with Lilly” SEC filing

“Total BAQSIMI ® sales growth, including units sold by Lilly in 2024 which were accounted for in other revenues, was 12%.” SEC filing

“...le and accrued liabilities increased primarily due to the increase in accrued customer fees and rebates associated with BAQSIMI ® sales, as we continued to assume distribution responsibilities for BAQSIMI ® from Lilly to our customers in the United States and certain other countries throughout 2024.” SEC filing

“Adcirca is shipped to customers in accordance with purchase orders received by Lilly.” SEC filing

“We sell Adcirca under an in-license from Lilly that expires December 31, 2026.” SEC filing

“Adcirca is manufactured for us by Lilly and distributed through its pharmaceutical wholesaler network on our behalf.” SEC filing